Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 8c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.75), $0.08 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Evolution Petroleum to buy Midland Basin mineral rights for $16M
• Freedom Capital Starts Hut 8 Mining Corp. (HUT) at Buy